Multimodal Vasopressor Strategy in Septic Shock
Key facts
- Who runs it
- University Medical Centre Maribor
- Where
- Croatia and Slovenia2 sites in 2 countriesChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 2/3
- People taking part
- 79 people enrolled
- Started
- 23 Dec 2023
- Ended
- 1 Feb 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Simultaneous administration of vasopressors
- Successive administration of vasopressors
- Record updated
- 31 March 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Adult patients (≥18 years)
- Sepsis (an acute change in total Sequential Organ Failure Assessment (SOFA) score ≥2 points consequent to infection) with persisting hypotension requiring vasopressors to maintain MAP ≥65 mm Hg and having a serum lactate level >2 mmol/L despite adequate volume resuscitation (20-30ml/kg in 3 hours)
- Vasopressor requirement of ≥0,15 μg/kg/min equivalent of norepinephrine base
- Patients are required to have central venous access and an arterial line present, and these are expected to remain present for at least the initial 72 hours of study
- Patients are required to have an urinary catheter present, and it is expected to remain present for at least the initial 72 hours of study
- Patients must have cardiac index (CI) >2.3 L/min/m2 (measured by bedside echocardiography, pulse contour cardiac output (PiCCO) or Swan-Ganz catheter)
Who cannot take part
- Surgery expected for source of infection
- Liver failure with a Model for End-Stage Liver Disease (MELD) score of ≥30
- Patients with acute mesenteric ischemia or a history of mesenteric ischemic
- Patients with Raynaud's phenomenon, systemic sclerosis or vasospastic disease
- Patients with active bleeding and an anticipated need (within 48 hours of initiation of the study) for transfusion of >4 units of packed red blood cells
- Patients with a known allergy to mannitol
- Death expected <24 hours
- Pregnancy (suspected or confirmed)
- Inter-hospital transfer expected during first 72 hours of hospitalization
- Patients on veno-arterial (VA) ECMO
This trial has no sites in United States.
It has sites in 2 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this prospective randomized controlled trial is to compare the effects of classic stepwise vs. early balanced multimodal vasopressor strategies in septic shock.
The 2 groups in the trial
- STEPWISE VASOPRESSOR SEPTIC SHOCK MANAGEMENTExisting treatment, for comparison
Regimen: Norepinephrine increases of 0.05-0.1 mcg/kg/min up to 0.5 mcg/kg/min, followed by vasopressin (administered at a fixed dose of 0.03 IE/min). If MAP remains \< 65 mmHg, norepinephrine will be titrated above dose of 0.5 mcg/kg/min until MAP ≥ 65 mmHg. Maximum norepinephrine dose as per clinical team decision. Initiation of additional vasoactive drugs (epinephrine, Ang II methylene blue or dopamine) as per clinical team decision. Initiation of inotropes (dobutamin, levosimendan, milrinone) as per clinical team decision.
Treatment: Successive administration of vasopressors
- BALANCED MULTIMODAL VASOPRESSOR SEPTIC SHOCK MANAGEMENTTreatment being tested
Regimen: Simultaneous administration of norepinephrine, angiotensin II and vasopressin at equivalent starting doses (equivalent to approximately 0.05 mcg/kg/min of norepinephrine). Increments of 0.05 mcg/kg/min of equivalent doses of all three vasopressors every 3-5 min until MAP ≥ 65 mmHg is reached (vasopressin will be administered at a maximum dose of 0.03 IE/min, AT II will be administered at a maximum dose of 100 ng/kg/min). Initiation of additional vasoactive drugs (epinephrine, methylene blue or dopamine) as per clinical team decision. Initiation of inotropes (dobutamin, levosimendan, milrinone) as per clinical team decision.
Treatment: Simultaneous administration of vasopressors
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Simultaneous Administration of Norepinephrine, Angiotensin II, and Vasopressin in Septic Shock Patients
- Publications
- Record updated
- 31 March 2026